N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide
中文名称 | N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide |
---|---|
中文同义词 | N-(4-氯-3-(三氟甲基)苯基)-3-氧代丁酰胺;化合物FASENTIN;FASENTIN,GLUT1 / GLUT4抑制剂 |
英文名称 | N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide |
英文同义词 | N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide;Fasentin;Fasentin - CAS 392721-37-8 - Calbiochem;Fasentin NEW;Fasentin >=98% (HPLC);anti-angiogenic,glucose,factor,Glucose transporter,inhibit,phase,necrosis,tumor,Fasentin,transport,GLUT,Inhibitor,G0/G1,FAS;Butanamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxo- |
CAS号 | 392721-37-8 |
分子式 | C11H9ClF3NO2 |
分子量 | 279.64 |
EINECS号 | |
相关类别 | |
Mol文件 | 392721-37-8.mol |
结构式 | ![]() |
N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide 性质
沸点 | 394.2±42.0 °C(Predicted) |
---|---|
密度 | 1.411±0.06 g/cm3(Predicted) |
储存条件 | room temp |
溶解度 | 二甲基亚砜:>10mg/mL |
形态 | 粉末 |
酸度系数(pKa) | 10.76±0.46(Predicted) |
颜色 | 白色至类白色 |
稳定性 | DMSO中的溶液可在-20°下稳定储存3个月。 |
GLUT4 68 μM (IC 50 ) |
GLUT1
|
Fasentin (0.1-1000 μM; 72 hours) inhibits endothelial, tumour and fibroblast cell growth without inducing cell death.
Fasentin (25-100 μM; 16-24 hours) induces a cell cycle arrest in G0/G1 phase and reduces the cell number in S phase in a dose-dependent manner.
Fasentin (50 μM; 16 hours) alters expression of genes associated with glucose deprivation such as AspSyn and PCK-2.
Fasentin (15, 30, 80 μM; pretreatment 1 hour) induces glucose deprivation, partially blocks glucose uptake in PPC-1, DU145, and U937 cells.
Fasentin (100 μM; 16 hours) does not affect the migratory capability of endothelial cells.
Fasentin (25-100 μM; 16 hours) lowers levels of phospho-ERK in HMECs, indicating a partial inhibition on the ERK signalling pathway, even though the effect is not statistically significant. Fasentin does not inhibit the tyrosine kinase activity of VEGFR2.
Fasentin interacts with a unique site in the intracellular channel of GLUT1.
Cell Viability Assay
Cell Line: | Three types of endothelial cells ECs (HMEC, human microvascular endothelial cells; HUVEC, human umbilical vein endothelial cells; and BAEC, bovine aortic endothelial cells), three human tumour cell lines (MDA-MB-231 and MCF7 breast carcinoma cells, and HeLa cervix adenocarcinoma cells), and human gingival fibroblasts (HGF) |
Concentration: | 0.1, 1, 10, 100, 1000 μM |
Incubation Time: | 72 hours |
Result: | Inhibited endothelial, tumour and fibroblast cell growth (IC 50 =26.3-111.2 μM) without inducing cell death. |
Cell Cycle Analysis
Cell Line: | HMECs |
Concentration: | 25, 50, 100 μM |
Incubation Time: | 16, 24 hours |
Result: |
Induced a cell cycle arrest in G0/G1 phase and reduced the cell number in S phase in a dose-dependent manner.
Did not increase the subG1 population. |
RT-PCR
Cell Line: | PPC-1 cells [2] |
Concentration: | 50 μM |
Incubation Time: | 16 hours |
Result: | Altered expression of genes associated with glucose deprivation such as AspSyn and PCK-2 not FLIP mRNA expression. |
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/04/30 | HY-101849 | N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide Fasentin | 392721-37-8 | 5mg | 700元 |
2024/04/30 | HY-101849 | N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide Fasentin | 392721-37-8 | 10mM * 1mLin DMSO | 770元 |